Assertio Therapeutics (ASRT) Stock Statistics & Valuation Metrics

Assertio Therapeutics has a market cap or net worth of $150.70M. The enterprise value is $158.07M.

Assertio Therapeutics has 6,462,180 shares outstanding. The number of shares has decreased by -2.65% in one year.

Assertio Therapeutics’s return on equity (ROE) is -0.32 and return on invested capital (ROIC) is -12.35%.

The current PE Ratio of Assertio Therapeutics is ―. Assertio Therapeutics’s PEG ratio is -0.05.

In the last 12 months, Assertio Therapeutics had revenue of 118.71M and earned -30.38M in profits. Earnings per share was -4.74.

In the last 12 months, operating cash flow was -7.08M and capital expenditures 0.00, giving a free cash flow of -7.08M billion.

Assertio Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Assertio Therapeutics upcoming earnings date is Jul 30, 2026, Before Open (Confirmed).

Assertio Therapeutics as a current ratio of 1.70, with Debt / Equity ratio of 53.30%

In the past 12 months, Assertio Therapeutics has paid 435.00K in taxes.

Assertio Therapeutics EV to EBITDA ratio is 6.80, with an EV/FCF ratio of -3.09.

Assertio Therapeutics has $71.57M in cash and marketable securities with $40.31M in debt, giving a net cash position of $31.26M billion.

Gross margin is 44.32%, with operating margin of -14.51%, and net profit margin of -25.59%.

The average price target for Assertio Therapeutics is $24.20, which is 11.43% higher than the current price. The consensus rating is Moderate Buy